	US 11,684,655 B2
	Methods of treating neutorpenia using G-CSF protein complex
Gajanan Bhat, Irvine, CA (US); Shanta Chawla, Irvine, CA (US); Jae Hyuk Choi, Gyeonggi-do (KR); Eun Jung Kim, Gyeonggi-do (KR); Yu Yon Kim, Gyeonggi-do (KR); Gyu Hyan Lee, Gyeonggi-do (KR); and Hyesun Han, Gyeonggi-do (KR)
Assigned to Spectrum Pharmaceuticals, Inc., Irvine, CA (US); and Hanmi Pharm Co., Ltd., (KR)
Filed by Spectrum Pharmaceuticals, Inc., Irvine, CA (US); and Hanmi Pharm Co., Ltd., Gyeonggi-do (KR)
Filed on Aug. 18, 2020, as Appl. No. 16/996,635.
Application 16/996,635 is a continuation in part of application No. 16/428,351, filed on May 31, 2019, granted, now 11,267,858.
Prior Publication US 2021/0008166 A1, Jan. 14, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/19 (2006.01); A61K 47/60 (2017.01); C07K 16/46 (2006.01)

CPC A61K 38/193 (2013.01) [A61K 47/60 (2017.08); C07K 16/46 (2013.01); C07K 2317/522 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/528 (2013.01); C07K 2317/53 (2013.01)]

22 Claims

1. A method of treating a condition in a subject in need thereof, the condition characterized by compromised white blood cell production in the subject, the method comprising administering to the subject a therapeutically effective amount of a chemotherapeutic regimen followed by a therapeutically effective amount of a protein complex comprising a modified human granulocyte-colony stimulating factor (hG-CSF) covalently linked to an immunoglobulin Fc region via a non-peptidyl polymer, wherein the non-peptidyl polymer is site-specifically linked to an N-terminus of the immunoglobulin Fc region and the modified hG-CSF comprises the amino acid sequence of SEQ ID NO: 1, wherein the protein complex is administered on the same day as the chemotherapeutic regimen.